Regularly Scheduled Series

Hematology Oncology Grand Rounds

Department of Medicine/Section of Hematology/Oncology

Course No. 25D12

Friday, March 7, 2025

8:00 am- 9:00 am

**\* \* \* ZOOM PRESENTATION \* \* \***

Join Zoom Meeting

<https://oklahoma.zoom.us/j/94190546610?pwd=yFZEdn3horA2JidtUUgaWEMYhDwZWT.1&from=addon>

Meeting ID: 941 9054 6610

Passcode: 17339999

**“Advances in Hereditary Hemorrhagic Telangiectasia”**

- - - - - - - - - - - - - - - - - - - -

Presented by:

**Hanny Al-Samkari, MD**

**Massachusetts General Hospital**

**Division of Hematology and Oncology**

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™.*  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

The University of Oklahoma is an equal opportunity institution. [www.ou.edu/eoo](http://www.ou.edu/eoo)

**Accommodation Statement:** For accommodations, please contact Robin Vinson at (robin-vinson@ouhsc.edu).

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

**Disclosure & Mitigation Report**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | |  | |
| **Role(s)** | **First Name** | **Last Name** | **Ineligible Company** | **Nature of the Financial Relationship** |
| Planning Committee | Unaiza | Zaman, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Course Contact | Robin | Vinson | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Planning Member/Moderator | Naoko | Takebe, MD, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Course Director | Mohammad | Khawandanah | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Speaker | Hanny | Al-Samkari, MD | Agios; Amgen; Sobi; Novartis; Vaderis | Grant/research support |
| Agios; Amgen; Sobi; Novartis; Vaderis; Alpine; Alnylam; Argenx; Pharmacosmos; Sanofi; | Consulting Fee |
| Dr. Al-Samkari will be discussing experimental or off-label drugs, devices and/or therapies that have not been approved by the FDA. | | | | |